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Recently, a new locus (PARK8) for autosomal dominant parkinsonism has been identiﬁed in one large Japanese
family. Linkage has been shown to a 16-cM centromeric region of chromosome 12, between markers D12S1631
and D12S339. We tested 21 white families with Parkinson disease and an inheritance pattern compatible with
autosomal dominant transmission for linkage in this region. Criteria for inclusion were at least three affected
individuals in more than one generation. A total of 29 markers were used to saturate the candidate region. One
hundred sixty-seven family members were tested (84 affected and 83 unaffected). Under the assumption of het-
erogeneity and through use of an affecteds-only model, a maximum multipoint LOD score of 2.01 was achieved
in the total sample, with an estimated proportion of families with linkage of 0.32. This LOD score is signiﬁcant
for linkage in a replication study and corresponds to a P value of .0047. Two families (family A [German Canadian]
and family D [from western Nebraska]) reached signiﬁcant linkage on their own, with a combined maximum
multipoint LOD score of 3.33, calculated with an affecteds-only model (family A: LOD score 1.67, ;Pp .0028
family D: LOD score 1.67, ). When a penetrance-dependent model was calculated, the combined mul-Pp .0028
tipoint LOD score achieved was 3.92 (family A: LOD score 1.68, ; family D: LOD score 2.24,Pp .0027 Pp
). On the basis of the multipoint analysis for the combined families A and D, the 1-LOD support interval.0007
suggests that the most likely disease location is between a CA repeat polymorphism on genomic clone AC025253
(44.5 Mb) and marker D12S1701 (47.7 Mb). Our data provide evidence that the PARK8 locus is responsible for
the disease in a subset of families of white ancestry with autosomal dominant parkinsonism, suggesting that it
could be a more common locus.
Introduction
Parkinsonism (MIM 168600) is a clinical syndrome de-
ﬁned by a characteristic constellation of signs and symp-
toms, including bradykinesia, rigidity, resting tremor, and
postural instability. The most common cause of parkin-
sonism is Parkinson disease (PD). Patients with PD re-
spond to dopaminergic therapy. PD is pathologically char-
acterized by a selective degeneration of dopaminergic
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neurons of the substantia nigra, leading to a deﬁciency of
dopamine in their striatal projection areas. Characteristic
eosinophilic inclusions, termed “Lewy bodies” (LBs) are
the pathological hallmark required for a diagnosis of def-
inite PD (Gibb and Lees 1989).
A major breakthrough in recent years was the map-
ping and cloning of a number of genes that cause mono-
genically inherited forms of parkinsonism with different
associated pathologies and a variable, but overlapping,
spectrum of clinical signs and symptoms. Mutations in
the gene for a-synuclein are responsible for disease in
a small number of families with autosomal dominantly
inherited parkinsonism (PARK1 [MIM 168601]) (Po-
lymeropoulos et al. 1997; Kruger et al. 1998). Patients
with this mutation show typical levodopa-responsive
parkinsonism, but they also frequently show dementia
and, in some cases, other neurologic abnormalities
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(Spira et al. 2001). Pathologically, a-synuclein aggre-
gates in LBs, as in typical sporadic PD, but tau pa-
thology has also been recognized (Duda et al. 2002;
Ishizawa et al. 2003). Tau deposits in neurons and glial
cells are the major pathological abnormality observed
in affected individuals with frontotemporal dementia
and parkinsonism linked to chromosome 17 (FTDP-17
[MIM 600274]). Some of these families present clini-
cally with parkinsonism, although it is poorly respon-
sive to levodopa therapy. There are now 130 known
tau mutations found in 180 kindreds (Ghetti et al.
2003).
Although only two disease-causing mutations have
been found in the a-synuclein gene, a large number of
pathogenic mutations have been identiﬁed in the parkin
gene on chromosome 6 (PARK2 [MIM 60254]) (Kitada
et al. 1998). These mutations cause autosomal-recessive
early-onset parkinsonism, a form of the disease that is
characterized pathologically by a severe and selective de-
generation of dopaminergic neurons, usuallywithout LBs
(Ishikawa and Takahashi 1998; Mori et al. 1998), al-
though alternate pathologies have been described in com-
pound heterozygous cases (Farrer et al. 2001a; van der
Warrenburg et al. 2001; Morales et al. 2002). Parkin has
been found to function as a ubiquitin ligase (Shimura et
al. 2000), suggesting a key role of the ubiquitin-protein
degradation pathway in the molecular pathogenesis of
dopaminergic cell death. The importance of this pathway
is further emphasized by the discovery of a mutation in
another gene involved in protein ubiquitination, ubiq-
uitin C-terminal hydrolase (UCHL1; PARK5 [MIM
191342]), in a small family with parkinsonism (Leroy et
al. 1998). A nonsynonymous polymorphism (S18Y) in
that gene was found to be associated with a reduced risk
for developing PD (Maraganore et al. 1999).
Recently, mutations in the gene DJ-1 have been
found to cause another recessive form of early-onset
parkinsonism (PARK7 [MIM 602533 ]) (Bonifati et al.
2003). Several other loci for monogenic recessive and
dominant forms of inherited parkinsonism have been
mapped, but the respective genes have not been iden-
tiﬁed yet. One such locus for levodopa-responsive par-
kinsonism has been identiﬁed on chromosome 12, in
a large Japanese family with autosomal-dominant in-
heritance (PARK8 [MIM 607060]) (Funayama et al.
2002). Affected individuals in this family showed typ-
ical levodopa-responsive parkinsonism with onset in
their 50s. Pathologically, nigral degeneration was
found without distinctive inclusions.
Here we provide evidence that the PARK8 locus is
responsible for disease in a subset of families of white
ancestry with autosomal-dominant parkinsonism. How-
ever, on careful clinical examination, signs of dementia,
supranuclear gaze palsy, and motoneuron degeneration
were also found in some affected individuals, and path-
ological examination showed a range of a-synuclein and
tau pathology, suggesting a remarkably wide spectrum
of phenotypes of PARK8-linked parkinsonism.
Material and Methods
Clinical Studies
Twenty-one families with three or more affected per-
sons, consistent with autosomal dominant inheritance,
were included in the study. A description of the genea-
logical and clinical methods used in the study of par-
kinsonian kindreds are detailed elsewhere (Denson and
Wszolek 1995). Some of the families had been included
into linkage previously, with no evidence for linkage to
PARK1 and PARK3 in families A, D,M3, andM6. (Gas-
ser et al. 1997, 1998; T.G. and A.Z., unpublished ob-
servations). Disease in patients was diagnosed according
to the U.K. Brain Bank or Calne’s criteria (Calne et al.
1992; Daniel and Lees 1993).
Positron Emission Tomography (PET) Studies
PET studies were performed through use of an ECAT
953B scanner in 3-D mode with 6-[18F]ﬂuoro-L-dopa
(FD) on two affected and two unaffected members of
family D and with [11C]raclopride (RAC) on one affected
family member. Details on the PET studies will be pre-
sented elsewhere (D.B.C., J.S., and Z.W., unpublished
data).
Pathological Studies
Every effort was made to obtain ﬁxed and frozen brain
at autopsy, through use of standard methods (Ishizawa
et al. 2003). Previously collected pathological material
was retrieved and reexamined.
Genetic Studies
The following microsatellite markers on chromosome
12, spanning the published disease locus, were used (the
sex-averaged map positions, in centimorgans, are given
in parentheses): D12S310 (34.62), D12S1042 (46.52),
D12S87 (49.42), D12S345 (50.67), D12S1592 (54.17),
D12S1653 (54.54) D12S291 (54.99), D12S1301 (55.52),
D12S1663 (55.68), AC024934, AC025253, AC018923,
AC079033, AC08127, AC084878, AC025031,
AC008014, AC080136, D12S85 (58.42), AC0044861,
D12S1701 (59.70), AC008083, D12S1661 (60.66),
D12S2196 (60.67), D12S339, (60.84), D12S1635
(61.82), D12S1629 (62.43), D12S368 (63.15), and
D12S398 (65.69). The map positions of these markers
were obtained by calculating the arithmetic mean of the
sex-speciﬁc distances taken from the Genetic Location
Database, through use of MAP-O-MAT version 1.0b
(MAP-O-MAT Web site). To saturate the PARK8 region,
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Figure 1 Linkage analysis of all 21 pedigrees with autosomal
dominant Parkinson disease. Affecteds-only multipoint LOD scores
are summed across families.
we developed new polymorphic markers (underlined in
the above list) by searching the database for CA repeats
through use of in silico BAC sequence (University of Cal-
ifornia Santa Cruz [UCSC]HumanGenomeBrowserWeb
site). Since the genetic positions for these markers are not
deﬁned in the database, their positions were estimated by
linear interpolation.
Genomic DNA from peripheral blood lymphocytes
was extracted after obtaining informed consent from all
participating family members. DNA fragments contain-
ing the polymorphic marker sequences were ampliﬁed
by PCR (primer sequences are available upon request).
Fluorescently labeled PCR products were analyzed on
ABI 310 and ABI 377 automated sequencers with a ﬂuo-
rescence detection system. Linkage analysis was per-
formed using MLINK for pairwise and FASTMAP for
multipoint LOD scores in all families, allowing for ge-
netic heterogeneity. The admixture test was applied as
developed by Smith (1963).
Marker allele frequencies were based on all individ-
uals genotyped. If allele frequencies were based on
founders (estimated using ILINK), the results were not
signiﬁcantly different throughout. Differences were usu-
ally markedly less than 0.1 LOD units.
We assumed autosomal-dominant inheritance with an
age-dependant penetrance. Penetrance was set at 20%
for the decade between 20 and 30 years, 30% for the
decade between 30 and 40 years, and so forth. Individ-
uals aged 70 years were assigned to the class with the
highest penetrance, 70%. The frequency of the delete-
rious allele was set at 0.001. The estimates for the age-
dependent penetrances were based on two observations:
(1) that ages at onset seemed uniformly distributed over
all age decades except for the very youngest ones, in-
dicating a constant increase in penetrance over all rel-
evant age decades; and (2) that an overall estimate re-
sulted in a penetrance of 69.2% at the age of 70 years
(18/26 putative gene carriers affected). It should be noted
that these estimates are necessarily based on a selected
sample (pedigrees ascertained for linkage analysis) and
that this sample size is also limited. In two affected in-
dividuals, date of birth, age at death, and age at onset
were not available. These individuals were classiﬁed in
a separate liability class that contained only affected per-
sons. The phenocopy rate was set at 2% in individuals,
on the basis of the population prevalence of PD at 160
years (de Rijk et al. 1997). The P values given are nom-
inal P values. Since the models used here (affecteds-only
model, penetrance-dependent model, and penetrance-de-
pendent model with individuals classiﬁed as affected on
the basis of PET criteria) are not independent models,
we did not perform a Bonferroni correction. Neverthe-
less, the results would still be signiﬁcant even if Bonfer-
roni correction were applied.
Results
All 21 families were analyzed with a ﬁrst set of
known polymorphic markers (D12S310, D12S1042,
D12S87, D12S345, D12S1592, D12S1653, D12S291,
D12S1301, D12S1663, D12S85, D12S1701, D12S1661,
D12S2196, D12S339, D12S1635, D12S1629, D12S368,
D12S398). Signiﬁcant evidence for linkage was found,
with a maximum multipoint LOD score of 2.01, corre-
sponding to a P value of .0047, considering affectedmem-
bers only and allowing for genetic heterogeneity (ﬁg. 1).
The corresponding P value for the analysis with age-de-
pendent penetrance is .00119 (LOD score 2.56). Since
this is a replication study and only a deﬁned chromosomal
region is investigated, this LOD score exceeds the level of
signiﬁcance, , required for this type of analysisPp .01
(Lander and Kruglyak 1995). Thus, both of our models
give signiﬁcant evidence for linkage under heterogeneity,
even when a correction for multiple tests (two models
here) is performed.
Of these 21 families, 10 showed positive LOD scores
in this region, with the bulk of the evidence being de-
rived from two large families (family D, from western
Nebraska, and family A, of German Canadian origin)
that had previously been characterized clinically and
pathologically (Wszolek et al. 1995, 1997), whereas 11
families had negative LOD scores, of which 4 had LOD
scores !2, fulﬁlling the formal criteria for exclusion.
The estimate for the proportion of families with linkage
was 0.32, with the 95% CI ranging from 0.03 to 1.00.
This leaves open the possibility that some of the other
families may also have linkage to PARK8, although
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Figure 2 Pedigree structure of families A and D. Blackened symbols denote affected family members, and asterisks (*) indicate individuals
typed with polymorphic markers. For clarity, only part of each pedigree is shown. The complete pedigrees with detailed clinical descriptions
are shown elsewhere (Wszolek and Markopoulou 1999).
these families are too small to draw any deﬁnitive
conclusion.
The clinical characteristics of the 10 families with
positive scores are shown in table 1. The two largest
families (family A and family D; ﬁg. 2) showed signif-
icant linkage on their own by the Lander and Kruglyak
(1995) criteria. Therefore, they were chosen for further
delineation of the critical region. To reﬁne the candidate
region, new microsatellite repeats were identiﬁed from
the following chromosome 12 BAC clones: AC024934,
AC025253, AC018923, AC079033, AC08127,
AC084878, AC025031, AC008014, AC080136,
AC0044861, and AC008083. Two-point LOD scores
were calculated and showed the highest value for the
combined families (families A and D) at marker
D12S85, with a value of 4.89 (penetrance-dependent
model; table 2), and at marker AC08127, with value
of 3.14 (affecteds-only model; data not shown).
To deﬁne the candidate region further, parametric
multipoint linkage analysis was performed. The highest
values in an affecteds-only multipoint analysis were
achieved with LOD scores of 1.67 for family D (Pp
) and 1.77 for family A ( ), with the.0028 Pp .0022
respective peak in each family being 1.2 cM apart.
When we forced both peaks to occur at the same point,
the LOD scores were 1.67 for each family, with P values
of .0028 in each of the families (ﬁg. 3a). When we
calculated a penetrance-dependent model, the multi-
point analysis remained stable for family A, with the
highest LOD score value being 1.68 ( ),Pp .0027
whereas the LOD score in family D increased to 2.24
( ); both peaks were at an identical location,Pp .0007
only 0.24 cM away from the peak in the affecteds-only
analysis. (ﬁg. 3b). It is noteworthy that two clinically
unaffected individuals in family D who are aged 160
years carry the putative disease haplotype. One of these
two individuals was found to be affected on the basis
of PET criteria. To protect the privacy of these individ-
uals, the position in the pedigree is not shown. When
we considered this patient as affected, the LOD score
in family D increased from 2.24 to 2.79 (penetrance-
dependent model). The LOD score allowing for hetero-
geneity, calculated through use of this classiﬁcation and
all families, rises to 3.02 ( ).P ! .0004
The 1-LOD support interval for the disease-causing
locus, based on the affecteds-only multipoint analysis
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Table 2
Parametric Two-Point LOD Scores, for the Combined Families A
and D, between Autosomal Dominant Parkinsonism and Markers
of the PARK8 Region, Calculated under the Penetrance-Dependent
Model
MARKER
(POSITION IN CM)
LOD SCORE AT A RECOMBINATION
FRACTION OF
.00 .01 .05 .1 .2 .3 .4
D12S1592 (54.17) .05 .5 1.19 1.37 1.19 .75 .23
D12S291 (54.99) .59 .4 .35 .63 .68 .47 .16
D12S1301 (55.52) 2.05 2.0 1.38 1.61 1.13 .63 .19
D12S1663 (55.68) 1.80 1.04 .03 .48 .66 .49 .20
AC024943 3.54 3.73 3.78 3.5 2.61 1.54 .47
AC025253 .65 .64 .60 .53 .37 .22 .07
AC018293 .08 .08 .06 .02 .03 .03 .01
AC079033 2.9 2.84 2.6 2.27 1.58 .85 .23
AC08127 1.95 1.90 1.72 1.5 1.03 .57 .17
AC084878 4.29 4.22 3.9 3.47 2.52 1.47 .49
AC025031 2.19 2.42 2.62 2.5 1.97 1.25 .48
AC080140 4.67 4.60 4.28 3.86 2.88 1.78 .66
AC080136 1.56 1.52 1.38 1.20 .82 .43 .11
D12S85 (58.42) 4.89 4.79 4.39 3.85 2.71 1.51 .43
AC0044861 1.80 2.10 1.99 1.46 .82 .25 1.28
D12S1701 (59.70) 2.51 2.45 2.22 1.90 1.26 .65 .16
D12S1661 (60.66) .41 .07 .38 .55 .56 .38 .14
D12S2196 (60.67) .58 .03 .48 .63 .58 .36 .12
Figure 3 Multipoint LOD score plots for families A and D. The
X-axis represents location in centimorgans, and the Y-axis represents
LOD scores. LOD scores are shown for family A, family D, and both
families combined (AD). a, Affected-only model. b, Penetrance-de-
pendent model.
for the combined families A and D, is deﬁned by mark-
ers AC025253 (44.5 Mb) to D12S1701 (47.7 Mb). In
family A, LOD scores were close to the theoretical max-
imum. In family D, the maximummultipoint LOD score
was 2.24, substantially lower than the theoretical max-
imum of 6.27 (when we assumed the age-dependent
model) that could be obtained in this pedigree. This is
due to one deceased individual (individual III:15 in ﬁg.
2), whose haplotype was reconstructed from his three
living unaffected children and his living spouse. This
individual was affected with PD at age 49 years and
was treated with stereotactic surgery. His children car-
ried four different haplotypes, but none of them was
identical to the haplotype shared by all other affected
individuals in this pedigree. It therefore must be as-
sumed that this individual suffered from parkinsonism
of another cause. A similar case of a phenocopy was
found in the Contursi kindred (Polymeropoulos et al.
1996), the family in which a-synuclein was identiﬁed
as the disease gene.
Haplotype analysis in all 10 families supporting link-
age did not show any evidence, at the present resolution,
of allele sharing for the cosegregating chromosome, in-
dicating that, most likely, independent mutational events
have occurred.
It is interesting that neuropathologic examination of
affected individuals of families A and D showed var-
iable a-synuclein and tau pathology, indicating that
the PARK8 mutation may be associated with a range
of pathological phenotypes. Details on these exami-
nations are presented elsewhere (Wszolek et al. 2003).
Discussion
Genetic progress in unraveling the etiology of parkin-
sonism has been rapid, with the identiﬁcation of a-syn-
uclein (PARK1), parkin (PARK2), UCH-L1 (PARK5),
and DJ-1 (PARK7) gene mutations. Althoughmany fam-
ilies with dominant inheritance have been described, to
date, each of the mapped genetic loci accounts only for
a very small number of kindreds (Skipper and Farrer
2002).
PARK8 (Funayama et al. 2002) may be an exception.
Although linkage could be proven for only two of the
families in our study individually, LOD score calcula-
Zimprich et al.: PARK8 and Autosomal Dominant Parkinsonism 17
tions in the total sample of families under the assump-
tion of genetic heterogeneity leave open the possibility
that mutation(s) in the underlying disease gene, yet to
be identiﬁed, may explain a broader subset of the fam-
ilies with dominantly inherited PD. However, even if the
disease only in the two largest families of this study
were due to PARK8 mutations, this would be quite re-
markable, given the fact that only twomutational events
have been identiﬁed worldwide in the a-synuclein gene
and that other dominant PD loci also seem to be re-
stricted to a very small number of families.
All individuals included in the study as affected family
members satisfy criteria for the cardinal signs and symp-
toms of PD with positive response to L-dopa. However,
closer examination and longitudinal follow-up over
many years showed a broader range of phenotypes, in-
cluding dementia and amyotrophy (Wszolek et al. 1997,
2003). This is consistent with recent reports indicating
that clinical features associated with the Ala53Thr mu-
tation of the a-synuclein gene may clearly exceed the
core syndrome of parkinsonism and include dementia,
autonomic dysfunction, and other neurologic deﬁcits
(Spira et al. 2001).
The relationship between rare monogenic variants of
parkinsonism and the common sporadic disease is still
unclear. It is assumed that relatively common genetic
variants may increase susceptibility to the sporadic dis-
ease. To identify these polymorphisms, several genome-
wide screens have been performed in large numbers of
small families (usually affected sib pairs). These inves-
tigations provided suggestive evidence for linkage with
a number of chromosomal regions. So far, none of these
regions comprised the gene loci mapped in families with
dominant monogenic inheritance, indicating that these
genes may not contribute signiﬁcantly to the etiology
of PD in larger patient populations without clear Men-
delian inheritance (DeStefano et al. 2001; Scott et al.
2001; Li et al. 2002; Pankratz et al. 2002). On the other
hand, there is some evidence that polymorphisms in the
promoter region of a-synuclein may be associated with
a higher risk for PD (Farrer et al. 2001b) This question
also remains to be investigated for the PARK8 locus on
chromosome 12. It is interesting that genetic support
for the importance of this locus comes from the study
of Pankratz et al. (2002), in which evidence for linkage
to PARK8 is found in a subset of Parkin-positive fam-
ilies. Furthermore, an overlapping locus on chromo-
some 12 has recently been linked to dementia in families
containing at least one affected individual with LB dis-
ease (Scott et al. 2000). This raises the exciting possi-
bility that one and the same gene in the centromeric
region of chromosome 12 may cause both dominant
parkinsonism and dementia with LBs. This is, in fact,
supported by the pathological studies in the families in
our study (see below).
Despite the recent progress in gene identiﬁcation, the
molecular pathogenesis of PD is still unknown. How-
ever, genetic and biochemical evidence indicates that the
abnormal accumulation and aggregation of a-synuclein
(and possibly other proteins) and/or a deﬁciency of ubi-
quitinylation-dependent proteasomal protein degrada-
tion may play an important role in the process of nigral
cell death.
The demonstration of tau pathology in parkinsonism
caused by a-synuclein (Duda et al. 2002; Ishizawa et
al. 2003) and parkin (van de Warrenburg et al. 2001;
Morales et al. 2002) mutations indicates that pathways
to neurodegeneration may overlap; although there may
be a variety of insults, the cellular responses may be
more limited.
Autopsies were performed on several affected indi-
viduals from families A and D, shown here to have
linkage to PARK8. It is interesting that four different
types of pathological features were observed in family
D: one individual had LB pathology restricted to the
brain stem, as in idiopathic PD; one had widespread LB
pathology, as in dementia with LBs; one had tau pa-
thology resembling PSP; and one had only nigral de-
generation (Wszolek et al. 2003). Two individuals from
family A also demonstrated the presence of ubiquitin
and eosinophilic inclusions, but without classic LBs seen
in affected brain areas (Wszolek et al. 1997).
These observations may shed light on the complex ge-
notype-phenotype relationship in neurodegenerative dis-
orders. The ﬁndings in the families in our study indicate
that a single genetic defect may cause a remarkably wide
range of pathology. On the other hand, distinct biologic
insults may lead to similar pathology: although LBs are
described as the pathological hallmark of PD, they are
also found at autopsy in prion disease, type 1 neurode-
generation with brain iron accumulation, Down syn-
drome, and in some patients with Alzheimer disease who
carry an amyloid precursor protein mutation (Lantos et
al. 1994; Bugiani et al. 2000; Neumann et al. 2000; Si-
mard and van Reekum 2001). Identiﬁcation of the gene
product of PARK8 will undoubtedly contribute to our
understanding the basis of variable clinicopathological
ﬁndings found in these kindreds.
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